Join to view full profile
1275 York AveNew York, NY 10065
Phone+1 646-227-3813
Fax+1 646-888-4265
Dr. Konner is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jason Konner specializes in Oncology, with a subspecialty in Gynecologic Cancer. He is currently based in New York and serves as a professor at Early Drug Development. Dr. Konner completed his fellowship in Hematology and Medical Oncology at the Memorial Sloan Kettering Cancer Center, after a residency in Internal Medicine at the Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital. He attended Stanford University School of Medicine and earned his undergraduate degree from Yale College. Dr. Konner's experience lies in hereditary breast/ovarian cancer and gynecologic cancer. He has a number of significant publications and has participated in several clinical trials, primarily focused on different types of cancer.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1999 - 2001
Stanford University School of MedicineClass of 1999
Yale CollegeBS, 1990 - 1994
Certifications & Licensure
FL State Medical License 2023 - Present
CO State Medical License 2026 - 2027
NJ State Medical License 2016 - 2027
NY State Medical License 2000 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
- CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017
Clinical Trials
- Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
- Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
- Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Publications & Presentations
PubMed
- Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer.Matthew L Flint, Anna Shvygin, Paul Johannet, Seth Cohen, Jason Konner
International Journal of Gynecological Cancer. 2026-07-01 - 15 citationsA Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.Angela K Green, Qin Zhou, Alexia Iasonos, William A Zammarrelli 3rd, Britta Weigelt
Clinical Cancer Research. 2025-06-03 - 3 citationsPatient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.Paul Johannet, Matthew Flint, M Herman Chui, Jason Konner, Claire Friedman
Gynecologic Oncology. 2025-04-01
Journal Articles
- A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, intravenous/intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian CancerRoisin E O'Cearbhaill, Dmitriy Zamarin, Paul J Sabbatini, William P Tew, Carol Aghajanian, Jason A Konner, Gynecologic Oncology
Press Mentions
5 Warning Signs of Ovarian Cancer Every Woman Should KnowJune 23rd, 2022- I Promised My Sister I Would Write About How She Chose to DieJanuary 4th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
